$ONCY
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Healthcare
Sector
Biotechnology
Industry
Jared Kelly
CEO
28
Employees
$0.96
Current Price
$100.36M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 2 | 2 | $15,148.00 | 15,050 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 2 | 2 | $15,148.00 | 15,050 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 10 | 13 | $258,845.06 | 304,282 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 10 | 14 | $362,615.06 | 404,282 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | Parsons James T. Director | Purchase | 10,000 | $1.03 | $10,300.00 | View Details |
| Mar 12, 2026 | Kelly Jared Director | Purchase | 5,050 | $0.96 | $4,848.00 | View Details |
| Feb 11, 2026 | Kelly Jared Director | Purchase | 5,600 | $0.84 | $4,681.60 | View Details |
| Feb 12, 2026 | Kelly Jared Director | Purchase | 29,500 | $0.84 | $24,839.00 | View Details |
| Feb 12, 2026 | Look Kirk Chief Financial Officer | Purchase | 12,000 | $0.84 | $10,104.00 | View Details |
| Feb 12, 2026 | Pisano Wayne Director | Purchase | 30,000 | $0.84 | $25,338.00 | View Details |
| Feb 12, 2026 | Heineman Thomas Charles Chief Medical Officer | Purchase | 12,132 | $0.83 | $10,033.16 | View Details |
| Feb 12, 2026 | Brown Deborah Margaret Director | Purchase | 25,000 | $0.85 | $21,240.00 | View Details |
| Feb 12, 2026 | Hagerman Allison VP, Product Development | Purchase | 10,000 | $0.83 | $8,298.00 | View Details |
| Feb 12, 2026 | Seizinger Bernd R. Director | Purchase | 40,000 | $0.85 | $33,864.00 | View Details |
| Feb 11, 2026 | Seizinger Bernd R. Director | Purchase | 60,000 | $0.83 | $49,590.00 | View Details |
| Feb 11, 2026 | Aromando Andrew Chief Business Officer | Purchase | 29,600 | $0.86 | $25,417.52 | View Details |
| Feb 12, 2026 | Andrews Patricia S Director | Purchase | 35,400 | $0.86 | $30,291.78 | View Details |
| Jan 16, 2026 | Seizinger Bernd R. Director | Purchase | 100,000 | $1.04 | $103,770.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.06
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: